SG/CALL/BRISTOL-MYERS SQUIBB/62/0.1/20.09.24

SG/CALL/BRISTOL-MYERS SQUIBB/62/0.1/20.09.24 Share Price

DE000SU2KKY7

Market Closed - Deutsche Boerse AG 01:11:09 15/06/2024 am IST
0.011 ^EUR	0.00%

Current month	+37.50%
1 month	-26.67%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/62/0.1/20.09.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment	14/06	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	14/06	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	14/06	DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	14/06	BU

More news

Quotes 5-day view

Date	Price	Change
14/24/14	0.011	0.00%
13/24/13	0.011	-8.33%
12/24/12	0.012	+9.09%
11/24/11	0.011	+37.50%
10/24/10	0.008	0.00%

Delayed Quote Deutsche Boerse AG

Last update June 15, 2024 at 01:11 am IST

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SU2KKY
ISIN	DE000SU2KKY7
Date issued	21/11/2023
Strike	62 $
Maturity	20/09/2024 (97 Days)
Parity	10 : 1
Emission price	0.098 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	0.15 €
Lowest since issue	0.004 €
Spread	0.01 €
Spread %	47.62%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.2 USD

Average target price

53.19 USD

Spread / Average Target

+29.11%

Consensus